Increasing Adherence to Lung Cancer Screening

Description

Investigators are conducting a pragmatic randomized trial testing the effectiveness of patient and clinician nudge strategies on adherence to lung cancer screening (LCS) \& diagnostic follow-up across eligible primary care clinicians \& patients. Following the trial, a subsample of patients \& clinicians will be invited to one-time semi-structured interview \& survey to identify individual \& system-level factors that may restrict or enhance the impact of strategies.

Conditions

Lung Cancer, Adherence, Patient

Talk to us

Study Overview

On this page

Study Details

Study overview

Investigators are conducting a pragmatic randomized trial testing the effectiveness of patient and clinician nudge strategies on adherence to lung cancer screening (LCS) \& diagnostic follow-up across eligible primary care clinicians \& patients. Following the trial, a subsample of patients \& clinicians will be invited to one-time semi-structured interview \& survey to identify individual \& system-level factors that may restrict or enhance the impact of strategies.

Increasing Equitable Adherence to Annual Lung Cancer Screening and Diagnostic Follow-up

Increasing Adherence to Lung Cancer Screening

Condition
Lung Cancer
Intervention / Treatment

-

Contacts and Locations

Philadelphia

University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. are practicing primary care or specialty care physicians at a recruiting site within the University of Pennsylvania Health System;
  • 2. care for patients who completed LCS via LDCT in 2019-2023; and
  • 3. do not opt-out of study participation.
  • 1. are eligible for LCS based on 2021 US Preventive Services Task Force (USPSTF) population guidelines (aged 50-80; smoking history of 20-pack years; smoked within the last 15 years)
  • 2. completed LCS via LDCT in 2019-2023;
  • 3. have not been diagnosed with lung cancer;
  • 4. meet criteria for non-adherence;
  • 5. remain eligible for LCS during the trial enrollment period; and
  • 6. receive LCS care from a clinician that has not opted-out of study participation

Ages Eligible for Study

50 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Abramson Cancer Center at Penn Medicine,

Katharine Rendle, PhD,MSW,MPH, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Anil Vachani, MD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Study Record Dates

2024-11-10